Plasmacytomas of the NZB mouse

Area of Science:

• Immunology
• Oncology
• Animal Models

Background:

• Plasmacytomas are monoclonal tumors of plasma cells.
• Pristane (2, 6, 10, 14-tetramethylpentadecane) is a known inducer of plasmacytomas in mice.
• NZB mice are a distinct inbred strain with unique immunological characteristics.

Purpose of the Study:

• To investigate the efficacy and characteristics of pristane-induced plasmacytomas in NZB mice.
• To compare plasmacytoma development in NZB mice with that in BALB/c mice.
• To analyze the immunoglobulin class and binding specificity of paraproteins produced by NZB plasmacytomas.

Main Methods:

• Induction of plasmacytomas in NZB mice using three intraperitoneal inoculations of pristane.
• Comparison of tumor development latency, paraprotein frequency, and immunoglobulin classes with historical data from BALB/c mice.
• Analysis of carbohydrate-binding specificities of paraproteins.
• Serial transplantation of ascites tumors to assess immunoglobulin production stability.

Main Results:

• Plasmacytomas were successfully induced in NZB mice with pristane.
• NZB mice exhibited a significantly longer latent period for tumor development compared to BALB/c mice.
• NZB tumors showed a reduced frequency of IgA paraproteins and an increased frequency of IgG paraproteins (IgG1, IgG2a, IgG2b, IgG3).
• The frequency of carbohydrate-binding paraproteins was 10-fold lower in NZB mice.
• Primary ascites frequently contained multiple paraproteins, but individual tumors did not produce more than one immunoglobulin class upon serial transplantation.

Conclusions:

• NZB mice are susceptible to pristane-induced plasmacytomas, but the induction kinetics and resulting tumor characteristics differ from BALB/c mice.
• The altered immunoglobulin profile in NZB plasmacytomas suggests strain-specific B-cell responses or oncogenic pathways.
• These findings highlight the importance of mouse strain in plasmacytoma induction models and provide insights into B-cell malignancies.